Fibroheal raises ₹14 crore seed round to enter developed markets
What's the deal? Bengaluru-based Fibroheal WoundcareDealroom has a profile for this one. Try Dealroom → has raised ₹14 crore ($1.68 million) in a seed round to expand into developed markets and strengthen its position in advanced wound care. The company makes silk-based biomaterials for wound management.
Who's backing it? The round drew existing investors, including Dr. Naresh Bhat, wealth manager Joseph Thomas, and co-founder Bharat Tandon, who previously built VETCARE before its exit to CargillDealroom has a profile for this one. Try Dealroom →. Vikas K. S. and chief executive officer Vivek Mishra also put in capital.
By the numbers: Fibroheal reported 77% revenue growth in the first quarter of FY 2026–27 against the same period a year earlier. Its products are now used in more than 500 hospitals across India, and it has treated more than 150,000 patients to date.
Why now? The company is pushing beyond India. It partnered with US-based SYLKE in February 2025, and a study is under way at Johns Hopkins on silk protein-based solutions for donor sites.
What's the endgame? Fibroheal said the funds will strengthen its commercial capabilities, expand into global markets, and advance its work in biomaterial and regenerative wound care. It holds nine granted patents and more than 30 academic collaborations.
Track record: In mid-2025, early backer Telama Investment exited with a 29.6% internal rate of return. The company's investor base has included KITVEN Funds, C-CAMP, BIRACDealroom has a profile for this one. Try Dealroom →, and the Central Silk Board.
The signal: At $1.68 million, this seed sits in the 27th percentile by amount — modest capital for a medtech aiming at developed markets. Fibroheal's bet is that a proven product and revenue growth, rather than a large war chest, can carry it into more competitive healthcare systems abroad.
Read more: Startup Story Media
Image credit: Generated with Gemini
